S. Badarinath

发表

Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.

J. Hainsworth, A. Grothey, S. Sarkar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

C. Slingluff, K. Lewis, J. Travers, 2021, Journal for ImmunoTherapy of Cancer.

Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

D. Solit, E. Vakiani, L. Saltz, 2012, Clinical colorectal cancer.

Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.

B. Childs, L. Schwartzberg, S. Badarinath, 2014, Clinical breast cancer.

Phase II study of lapatinib in combination with vinorelbine , as first or second-line therapy in women with HER 2 overexpressing metastatic breast cancer

M. Desilvio, H. Chew, L. Schwartzberg, 2014 .

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

M. Desilvio, H. Chew, L. Schwartzberg, 2014, SpringerPlus.

Phase II Multicenter Study of Docetaxel and Bevacizumab ± Trastuzumab as First-Line Treatment of Patients With Metastatic Breast Cancer

B. Childs, L. Schwartzberg, S. Badarinath, 2013 .

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer

L. Hart, H. Burris, D. Yardley, 2013, Breast Cancer Research and Treatment.

Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002).

S. Dakhil, T. Cosgriff, R. Boccia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial.

C. Langer, E. Mitchell, S. Badarinath, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

R. Rifkin, A. Cartmell, J. Berenson, 2017, American journal of hematology.

Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.

S. Dakhil, T. Cosgriff, R. Boccia, 2010, Clinical colorectal cancer.

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

D. Solit, E. Vakiani, L. Saltz, 2012, Clinical colorectal cancer.

3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)

J. Hainsworth, A. Grothey, J. Yi, 2007 .